학술논문
Economic and budgetary impact evaluation of isavuconazole (Cresemba® ) versus voriconazole (Vfend® ) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system
Document Type
Article
Author
Source
In: PLoS ONE . (PLoS ONE, March 2024, 19(3 March))
Subject
Language
English
ISSN
19326203